Immunitybio Inc (IBRX) Stock Price, Quote & News

Company Profile

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead b...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 696 5235

Website: immunitybio.com

Address:

3530 John Hopkins Court, San Diego, United States

Biofrog Feb. 3 at 4:07 AM

$IBRX So this squeeze thing is freaky regarding retail shares. Just round numbers. 75% insider, not selling. 15% tutes, little or no selling. Retail 10% exposed to crazy squeeze numbers. Those of us that hold could be driving the car.

3 · Reply

rubraquercus Feb. 3 at 3:52 AM

$IBRX https://www.facebook.com/share/v/1CFB86DexS/

0 · Reply

Floridahurricanehater Feb. 3 at 3:50 AM

$QQQ $SPY IBRX. Alex Trubeck cancer treatment allowed him to work longer than normal treatment - Google Search $IBRX. Still amazing to me that he lived all that time and everyone I know that got it lived less than 6 months. Most about 3. And yet this treatment is not fda approved. https://www.google.com/search?q=Alex+Trubeck+cancer+treatment+allowed+him+to+work+longer+than+normal+treatment&ie=UTF-8&oe=UTF-8&hl=en-us&client=safari#lfId=ChxjMe

0 · Reply

h8888l Feb. 3 at 3:49 AM

$IBRX will done!!!

0 · Reply

XRPHomie Feb. 3 at 3:48 AM

$IBRX https://youtu.be/jY7AUFpnQJQ?si=6nkVgVUGsceC18Qr

0 · Reply

cyberInvest Feb. 3 at 3:42 AM

$IBRX not my material. From a reddit post last week. ST does not allow its full quotation or link. A gamma squeeze is where things stop behaving like a normal short squeeze and start behaving like a mathematical chain reaction. Since you already have the short‑squeeze mechanics mapped out, adding a gamma overlay lets you see how the price can accelerate far beyond what short covering alone would produce. assumptions: 70% insider ownership (not for sale) 40% short interest of the float IBRX float ≈ 284M shares Shorts ≈ 113.6M shares Options market becomes the accelerant

1 · Reply

Friarfan Feb. 3 at 3:41 AM

$IBRX 👀

0 · Reply

Deejayshin Feb. 3 at 3:38 AM

$IBRX My guess is Doc PSS, itinerary: 1st stop: London 2nd stop: Saudi Arabia 3rd stop: New Jersey 4th stop: Washington 5th stop: Back to West Coast

0 · Reply

Judykay Feb. 3 at 3:36 AM

$IBRX Night All I need to remember is Neupogen👉neutrophil Epogen👉RBC Big missing important part ANKTIVA👉NK cell IL 15 Wish I could explain to many that do not understand it. Go chatgpt it. Thank you, mom, for forcing me to go to nursing school when I really didn't like it, those nursing professors were so mean and made me learn everything and so did those doctors who liked to quiz me during clinical rotation in the OR and scream at me for not answering quickly enough. Oh, and to all the docs I called on as a pharma rep, when you liked hunting pharmaceutical reps for GAME. I learned a lot during my lifetime.

0 · Reply

roaringcharts Feb. 3 at 3:20 AM

$IBRX Dr. Patrick Soon-Shiong is revolutionizing oncology, transforming YOUR immune system into an unstoppable force against cancer. The ultimate nemesis has been set loose. https://x.com/i/status/2018501786840236413

0 · Reply

These 10 Stocks Could Be Short Squeeze Targets: Lucid, Kohl's, Avis and More

CAR KSS LCID CHH HIMS MARA TMDX

Feb 2, 2026, 7:00 AM EST - 16 hours ago

ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas

Jan 23, 2026, 7:00 AM EST - 10 days ago

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

Jan 20, 2026, 1:47 PM EST - 13 days ago

FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer

Jan 20, 2026, 8:46 AM EST - 13 days ago

Top 3 Health Care Stocks You May Want To Dump In January

VERO

Jan 20, 2026, 4:00 AM EST - 13 days ago

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

Jan 16, 2026, 3:45 PM EST - 17 days ago

ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 16, 2026, 12:52 PM EST - 17 days ago

ImmunityBio Stock Soars On Cancer Trial Progress, FDA Timeline

Jan 16, 2026, 11:04 AM EST - 17 days ago

ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I‑Told‑You‑So

Jan 16, 2026, 10:41 AM EST - 17 days ago

Looking For A Short Squeeze? 10 Stocks Ready To Rocket

CAR CHH HIMS KSS LCID MARA PCT

Jan 16, 2026, 7:00 AM EST - 17 days ago

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

Jan 16, 2026, 7:00 AM EST - 17 days ago

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

Jan 16, 2026, 5:52 AM EST - 17 days ago

This Biotech Stock Is Up 100% This Year. Why It's Soaring Again Today.

Jan 15, 2026, 12:50 PM EST - 18 days ago

ImmunityBio: Why I Am Upgrading To A Buy For 2026

Jan 15, 2026, 12:43 PM EST - 18 days ago

ImmunityBio Clocks 700% Revenue Surge In 2025 From Lead Bladder Cancer Drug

Jan 15, 2026, 8:30 AM EST - 18 days ago

ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year

Jan 14, 2026, 8:30 AM EST - 19 days ago

Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer

Jan 14, 2026, 8:30 AM EST - 19 days ago

Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ

Jan 13, 2026, 8:30 AM EST - 20 days ago

ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Jan 12, 2026, 8:30 AM EST - 21 days ago

NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security

Dec 29, 2025, 9:00 AM EST - 5 weeks ago

ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”

Dec 16, 2025, 9:00 AM EST - 6 weeks ago

ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer

Dec 12, 2025, 12:00 PM EST - 7 weeks ago

ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy

Dec 12, 2025, 6:10 AM EST - 7 weeks ago

ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe

Dec 3, 2025, 5:00 AM EST - 2 months ago

A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs

Nov 19, 2025, 4:56 AM EST - 2 months ago

ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech

Nov 13, 2025, 9:00 AM EST - 2 months ago

New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations

Nov 4, 2025, 10:12 PM EST - 3 months ago

Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024

Oct 22, 2025, 1:42 PM EDT - 3 months ago

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

AI APLD ENVX HIMS PLUG RKT RXRX

Oct 3, 2025, 1:24 PM EDT - 4 months ago

ImmunityBio: A Small Bet Is Warranted

Sep 11, 2025, 12:26 PM EDT - 5 months ago

ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking

Sep 8, 2025, 8:30 AM EDT - 5 months ago

ImmunityBio's ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

Aug 26, 2025, 8:30 AM EDT - 5 months ago

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio's ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device

Aug 19, 2025, 8:30 AM EDT - 5 months ago

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID

Aug 13, 2025, 8:30 AM EDT - 6 months ago

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

Aug 11, 2025, 8:30 AM EDT - 6 months ago

ImmunityBio Announces Houston's Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients

Aug 5, 2025, 7:00 AM EDT - 6 months ago

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

Jul 25, 2025, 6:03 AM EDT - 6 months ago

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

Jul 25, 2025, 6:00 AM EDT - 6 months ago

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

Jul 21, 2025, 10:45 AM EDT - 7 months ago

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval

Jul 7, 2025, 9:43 PM EDT - 7 months ago

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Jun 12, 2025, 9:09 AM EDT - 8 months ago

ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze

Jun 3, 2025, 8:45 AM EDT - 8 months ago

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

Jun 2, 2025, 9:00 AM EDT - 8 months ago

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

May 27, 2025, 8:00 AM EDT - 8 months ago

ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

May 12, 2025, 6:30 AM EDT - 9 months ago

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

May 5, 2025, 5:05 PM EDT - 9 months ago

ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA

May 5, 2025, 9:21 AM EDT - 9 months ago

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

May 5, 2025, 6:30 AM EDT - 9 months ago

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

Biofrog Feb. 3 at 4:07 AM

3 · Reply

rubraquercus Feb. 3 at 3:52 AM

$IBRX https://www.facebook.com/share/v/1CFB86DexS/

0 · Reply

Floridahurricanehater Feb. 3 at 3:50 AM

0 · Reply

h8888l Feb. 3 at 3:49 AM

$IBRX will done!!!

0 · Reply

XRPHomie Feb. 3 at 3:48 AM

$IBRX https://youtu.be/jY7AUFpnQJQ?si=6nkVgVUGsceC18Qr

0 · Reply

cyberInvest Feb. 3 at 3:42 AM

1 · Reply

Friarfan Feb. 3 at 3:41 AM

$IBRX 👀

0 · Reply

Deejayshin Feb. 3 at 3:38 AM

$IBRX My guess is Doc PSS, itinerary: 1st stop: London 2nd stop: Saudi Arabia 3rd stop: New Jersey 4th stop: Washington 5th stop: Back to West Coast

0 · Reply

Judykay Feb. 3 at 3:36 AM

0 · Reply

roaringcharts Feb. 3 at 3:20 AM

0 · Reply

Judykay Feb. 3 at 3:20 AM

$IBRX Well, NFA but I don't see the dif between 5-6 to where this may be in a few years! 1100+ day club

0 · Reply

BixbyKnolls Feb. 3 at 3:15 AM

$IBRX This is good - share it-- https://youtu.be/5QYPW3edX28

1 · Reply

runflat Feb. 3 at 3:11 AM

$IBRX It's the next Blockbuster drug. Tell your cousin

0 · Reply

oceanviewhi Feb. 3 at 3:02 AM

$IBRX Dr Pat gave the Firehorse a treatment of Anktiva before the lunar year

0 · Reply

Skipper6 Feb. 3 at 2:57 AM

$IBRX ...Elon needs to be in on this with Dr. Pat!!

3 · Reply

QuantoL Feb. 3 at 2:50 AM

$IBRX another 1.4M?

1 · Reply

oceanviewhi Feb. 3 at 2:47 AM

$IBRX Bio Frog is right , we’re going to need more capacity. But , 2 million vials annually generates $70 Billion a year potentially, not including Vivabiocell.

1 · Reply

BixbyKnolls Feb. 3 at 2:47 AM

$IBRX Good stuff

0 · Reply

SourMouth Feb. 3 at 2:46 AM

$IBRX shorts, check this chart:

0 · Reply

10xBio Feb. 3 at 2:37 AM

$IBRX A message to the pumpers : Fuck off and stop penny flipping Get behind something bigger than yourself ! And a simple message to our resident shorts GAME on motherfuckers ! Let s see what you got.

1 · Reply

JanetBSmellin Feb. 3 at 2:36 AM

$IBRX Cool little strategy on TradingView for the dates 12/31/25 - 02/02/26. Volume Cluster Profile: Avg price: $6.54 ✅ Support: $5.54 Resistance: $8.27

1 · Reply

ThePrinze Feb. 3 at 2:32 AM

$IBRX hate to be the bearer of bad news on the London speculation, but his daughter just finished her PHD there, so he is likely there for her. Would be nice if he was making a deal while he is there, but that’s not the main reason he is there. Still very bullish, but just wanted to level set expectations for the trip.

6 · Reply

Market Cap	6.16B
Revenue (ttm)	14.75M
Net Income (ttm)	-413.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,803.80%
Debt to Equity Ratio	0.00

Volume	24,291,500
Avg Vol	29,043,756
Day's Range	N/A - N/A
Shares Out	984.97M
Stochastic %K	22%
Beta	0.03
Analysts	Strong Sell
Price Target	$11.80